Business Wire

Northern Data AG Sees Substantial Demand for Its Bitcoin Mining Services

Share

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) is currently seeing a substantial increase in demand for its bitcoin mining infrastructure services.

Bitcoin mining is the most important high-performance computing (HPC) application to date. Consequently, with its global infrastructure solutions in the field of HPC, Northern Data serves many customers in the field of bitcoin mining, including several multibillion-dollar listed corporations.

With the rise of Bitcoin as an essential asset class and the associated need for computing capacity for bitcoin mining, Northern Data benefits in two ways: First, the Company experiences a sharp increase in customer demand. Second, Northern Data has performance-linked remuneration in place with some of its clients, such that Northern Data is now directly profiting from the rise in the bitcoin price.

In addition to the existing facility in Texas, the capacities in the Lefdal mine in Norway, which launched in May 2018, are also about to be further expanded. And in Scandinavia alone, five new locations for high-performance computing and bitcoin mining are expected to begin operations over the coming months. Furthermore, multiple locations in North America, especially Canada, are in final stages of negotiation.

In addition to the further expansion of its bitcoin mining activities, the Company is also expanding into other applications of high-performance computing. The Company's GPU-based distributed computing cluster began operating earlier in December.

This GPU cluster will be scaled to computing power of 404 petaflops (FP64) by the end of Q1/2021, well ahead of the currently second fastest supercomputer in the world, the US "Summit", which has a computing power of 148.8 petaflops. Only the Japanese supercomputer Fugaku will be ahead of Northern Data's GPU cluster, at 537 petaflops.

CEO Aroosh Thillainathan comments: "With more than seven years of experience in bitcoin mining and innovative solutions for both mobile units and large-scale facilities, Northern Data has a technological edge over the competition like no other company in the market. This is the basis of our success. In addition to the basic remuneration model, our performance-driven revenues, with which we participate in a rising bitcoin price, give us additional upside that we have not yet taken into account in our guidance."

Earlier this week Northern Data released its guidance for the financial year 2021. The Company expects sales of EUR 350 million to EUR 400 million and EBITDA of EUR 100 million to EUR 125 million in 2021, based on contracts that have already been executed or are in the process of being concluded and without considering any additional upside from performance-linked revenues and earnings.

About Northern Data:

Northern Data AG develops and operates global infrastructure solutions in the field of high-performance computing (HPC). With its customer-specific solutions, the company provides the infrastructure for various HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, big data analytics, IoT or rendering. The internationally active company is today a leading provider of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. The company combines its self-developed software and hardware with a sustainable energy supply. The Northern Data group currently employs about 150 members of staff.

Disclaimer:

This press release does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities of Northern Data AG, nor does it constitute a securities prospectus of Northern Data AG. The information contained in this press release is not intended to serve as a basis for financial, legal, tax or other business decisions. Investment or other decisions should not be based solely on this press release. As with all business and investment matters, please consult qualified professional advice.

Language:

English

Company:

Northern Data AG

Thurn-und-Taxis-Platz 6

60313 Frankfurt/Main

Germany

Phone:

+49 69 34 87 52 25

E-mail:

info@northerndata.de

Internet:

www.northerndata.de

ISIN:

DE000A0SMU87

WKN:

A0SMU8

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Hanover, Munich (m:access), Stuttgart, Tradegate Exchange

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Northern Data AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
e-mail: hans.duerr@northerndata.de
Phone: +49 69 348 752 89

Investor Relations:
Sven Pauly
e-mail: ir@northerndata.de
Phone: +49 89 125 09 03 30

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye